Abstract: The present invention relates to nutrient compositions for mammals comprising L-glutamyl-L-glutamine.

Abstract: The present invention provides novel peptides of the formula X-A.sub.6 -B.sub.7 -C.sub.8 -D.sub.9 -E.sub.10 -F.sub.11 containing a novel (1-amino-2-hydroxy-2-heterocyclic) ethyl moiety of the formula XL.sub.2c at the E.sub.10 -F.sub.11 -position, X is a terminal group, and the remaining variables are amino acid residues. The present invention also provides novel intermediate compounds. These peptides are useful as renin inhibitors and as inhibitors of retroviral proteases. Renin inhibitors are useful for the diagnosis and control of renin-dependent hyperaldosterism, other renin-dependent cardiovascular disorders and ocular disorders. Inhibitors of retroviral proteases, such as the HIV-I protease, are useful for treating diseases caused by retroviruses, such as human acquired immunodificiency disease syndrome (AIDS).

Abstract: Compositions for and methods of treating muscle weakness and degeneration are described. Such compositions include myogenic cells which are administered by the described methods to one or more affected muscles.

Abstract: This invention relates to a nutrient composition containing a dipeptide and method for administering the same. Particularly, this invention relates to a dipeptide tyrosyl-arginine, comprised of the amino acids tyrosine and arginine and the use of this dipeptide as a nutrient supplement to intravenous nutrition.

Abstract: Methods for the treatment of allergic reactions are provided, wherein a pharmaceutically effective dose of gamma interferon is administered to a patient within a predetermined temporal period prior to or following exposure to an allergen.

Abstract: The present invention relates to methods for improving cheese production by utilizing plasmin-regulating agents to maintain milk plasmin concentration in milk used to make cheese at that found at early lactation or at less than 0.2 mg/l milk.

Abstract: This invention relates to collagen compositions and methods of preparing such compositions. This invention also relates to a novel source of collagen, the common digital extensor tendon.

Abstract: A composition for use in inducing binding between parts of mineralized tissue by regeneration of mineralized tissue on at least one of the parts, containing as an active constituent a protein fraction originating from a precursor to dental enamel, so called enamel matrix;a process for inducing binding between parts of living mineralized tissue by regeneration of mineralized tissue on at least one of the parts using such composition.

Abstract: Pharmaceutical compositions useful for the treatment or prophylaxis of Gram-negative bacteremia or septic shock contain a bactericidal effective amount of polyclonal immunoglobulins against Gram-negative bacteria and a blood clot-dissolving effective amount of protein C. The compositions may further contain one or more protein C cofactors and monoclonal antibodies against Gram-negative bacterial endotoxins.A method for the treatment or prophylaxis of Gram-negative bacteremia or septic shock comprises administering, either together or separately, a bactericidal effective amount of polyclonal immunoglobulins against Gram-negative bacteria and a blood clot-dissolving effective amount of protein C. The method may optionally include administering one or more protein C cofactors and monoclonal antibodies against Gram-negative bacterial endotoxins.

Abstract: A process for the production of gelatin from fish skins comprises the steps of: (a) cleaning the skins in order to remove therefrom substantially all superfluous material; (b) treating with dilute aqueous alkali; (c) washing with water until the washing water is substantially neutral; (d) treating with dilute aqueous mineral acid; (e) washing with water until the washing water is substantially neutral; (f) treating with dilute aqueous citric acid and/or another suitable organic acid; (g) washing with water until the washing water is substantially neutral; and (h) extracting with water at elevated temperatures not above about 55.degree. c., the washed citric acid-treated skins. In practice, the present process employs much lower temperatures than known heretofore for the treatment steps, which results in a high quality product (e.g. absence of a fishy smell), compared with the prior art.

Abstract: Apolipoproteins are isolated from human blood plasma fractions which contain apolipoproteins by suspending these fractions in buffer solutions. The suspensions are subsequently incubated with a lower aliphatic alcohol, either with or without an organic solvent. The phase which contains the lipoproteins is separated and concentrated. The products obtained according to the procedure may be used primarily for the treatment of cardiovascular diseases, in particular hypercholesterolemia.

Abstract: A therapeutic method for treating mammals by administering an effective dosage of a substance comprising interleukin 6 or interleukin 6 and interleukin 3 into the mammal for enhancing the growth of megakaryocytes and platelets.

Abstract: Inflammation in mammals is treated by administering anti-inflammatory agent complexed with corticosteroid binding globulin (CBG).

Abstract: An anticoagulant containing as active ingredients protein C or activated protein C and heparin has a high anticoagulant activity which cannot be obtained with activated protein C or heparin alone. The activity of the anticoagulant is further increased by addition of AT III.

Abstract: The present disclosure is directed to improved pharmaceutical compositions employing inteferon-gamma which have been treated to remove interferon-gamma inhibitory activity associated with such preparations. In addition, the present disclosure details treatment protocols, including the elevation of patient body temperature and the use of combined or sequential interferon-gamma treatments, to enhance inteferon-gamma efficacy and reduce the resistance associated with inteferon-alpha and/or beta therapy.

Abstract: A sustained-release preparation of indomethacin or interferon comprising the active ingredient in admixture with a pharmaceutically acceptable biodegradable carrier, particularly a carrier selected from collagen, gelatin, and a mixture thereof. Said preparation is particularly suitable for parenteral administration and can release the active ingredient in an effective amount for a long period of time.

Abstract: A pharmaceutical composition and method are provided for erythropoietin therapy, such as treatment of an anemic disease, wherein an effective amount of activin with two beta.sub.B chains formulated in a pharmaceutically acceptable carrier is administered to a patient or animal in need of such therapy. Preferably the activin is human and the composition is administered parenterally.

Abstract: A composition for use in inducing binding between parts of mineralized tissue by regeneration of mineralized tissue on at least one of the parts, containing as an active constituent a protein fraction originating from a precursor to dental enamel, so called enamel matrix;a process for inducing binding between parts of living mineralized tissue by regeneration of mineralized tissue on at least one of the parts using such composition.

Abstract: Inhibitors of phospholipase A.sub.2 activity at the cell-surface membrane whose molecular structure comprises a cell-permeable PLA.sub.2 -inhibitor moiety covalently bonded directly or indirectly to a physiologically acceptable carrier moiety which is effective to inhibit cell internalization of the cell-permeable PLA.sub.2 -inhibitor moiety, with the proviso that phosphatidylserine is not bonded indirectly via divalent dodecanedioyl to dextrane hydrazide.

Abstract: Method for increasing milk production in mammals including man, and/or for increasing the birth weight of their newborn and improving postnatal growth, according to which the female mammal is supplied during pregnancy with an effective amount of hGRF or of one of its analogs, or alternatively of an active fragment of hGRF or of one of its analogs.The treatment is of short duration, for example from 10 to 20 days. Its effects are lasting and extend throughout the lactation period.Application to the treatment of animals of ovine, caprine, bovine or porcine species.